PMID- 21220609
OWN - NLM
STAT- MEDLINE
DCOM- 20110323
LR  - 20220410
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 29
IP  - 5
DP  - 2011 Feb 10
TI  - Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic 
      implications.
PG  - 475-86
LID - 10.1200/JCO.2010.30.2554 [doi]
AB  - Molecular analyses of leukemic blasts from patients with acute myeloid leukemia 
      (AML) have revealed a striking heterogeneity with regard to the presence of 
      acquired gene mutations and changes in gene and microRNA expression. Multiple 
      submicroscopic genetic alterations with prognostic significance have been 
      discovered. Application of gene- and microRNA profiling has identified 
      genome-wide expression signatures that separate cytogenetic and molecular subsets 
      of patients with AML into previously unrecognized biologic and/or prognostic 
      subgroups. These and similar future findings are likely to have a major impact on 
      the clinical management of AML because many of the identified genetic alterations 
      not only represent independent prognosticators, but also may constitute targets 
      for specific therapeutic intervention. In this report, we review genetic findings 
      in AML and discuss their clinical implications.
FAU - Marcucci, Guido
AU  - Marcucci G
AD  - The Ohio State University, Comprehensive Cancer Center, Columbus, OH 43210, USA. 
      guido.marcucci@osumc.edu
FAU - Haferlach, Torsten
AU  - Haferlach T
FAU - Dohner, Hartmut
AU  - Dohner H
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110110
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (CCAAT-Enhancer-Binding Proteins)
RN  - 0 (CEBPA protein, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Nuclear Proteins)
RN  - 117896-08-9 (Nucleophosmin)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
EIN - J Clin Oncol. 2011 May 1;29(13):1798
MH  - CCAAT-Enhancer-Binding Proteins/genetics
MH  - Chromosome Aberrations
MH  - Gene Expression Profiling
MH  - Humans
MH  - Isocitrate Dehydrogenase/genetics
MH  - Leukemia, Myeloid, Acute/*genetics/pathology/therapy
MH  - MicroRNAs/analysis
MH  - Mutation
MH  - Nuclear Proteins/genetics
MH  - Nucleophosmin
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-kit/genetics
MH  - fms-Like Tyrosine Kinase 3/genetics
EDAT- 2011/01/12 06:00
MHDA- 2011/03/24 06:00
CRDT- 2011/01/12 06:00
PHST- 2011/01/12 06:00 [entrez]
PHST- 2011/01/12 06:00 [pubmed]
PHST- 2011/03/24 06:00 [medline]
AID - JCO.2010.30.2554 [pii]
AID - 10.1200/JCO.2010.30.2554 [doi]
PST - ppublish
SO  - J Clin Oncol. 2011 Feb 10;29(5):475-86. doi: 10.1200/JCO.2010.30.2554. Epub 2011 
      Jan 10.